Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 9/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886527 | 0.85 | TSHR (0.38) | THRBTSHRHPGDALDH1A1TP53 | |
| SCHEMBL3382912 | 0.81 | THRB (0.37) | THRBTSHRHPGDALDH1A1 | |
| SCHEMBL28073928 | 0.79 | THRB (0.38) | THRBTSHRHPGDALDH1A1TP53 | |
| SCHEMBL302801 | 0.78 | THRB (0.43) | THRBTSHRHPGDALDH1A1TP53 | |
| SCHEMBL8881160 | 0.78 | TSHR (0.38) | THRBTSHRHPGDALDH1A1TP53 | |
| SCHEMBL10784915 | 0.77 | THRB (0.32) | THRBTSHRHPGD | |
| SCHEMBL18921583 | 0.76 | HCAR2 (0.31) | TSHRALDH1A1TDP1 | |
| SCHEMBL30792577 | 0.76 | HCAR2 (0.48) | TSHRALDH1A1TP53HSD17B10TDP1 | |
| SCHEMBL3890154 | 0.76 | HCAR2 (0.31) | TSHRALDH1A1TDP1 | |
| SCHEMBL8614980 | 0.76 | TSHR (0.50) | THRBTSHRHPGDALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-8557888-B2 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2013-10-15 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | IVOCLAR VIVADENT AG (LI) | 2012-11-29 | — | — | US | disclosed |
| EP-2455059-A1 | Polymerisable compound having improved hardening depth | Ivoclar Vivadent AG (LI) | 2012-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302657-A1 | Polymerizable compositions with improved through-curing depth | NR4A2, NR2C2, NOS2 | THRB 1920/4885TSHR 3716/4885HPGD 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.